What We're Reading: Page 131
Industry reads hand-picked by our editors
Dec 09, 2021
Dec 08, 2021
Dec 07, 2021
-
C&EN
Another year of pharma
-
Endpoints News
Meet 20 extraordinary women who are supercharging biopharma R&D
-
The New York Times
Biden Focuses on How Spending Bill Would Lower Drug Costs
-
The San Diego Union-Tribune
Richard Lerner, who led Scripps Research to greatness, dies at 83
Dec 06, 2021
-
The Wall Street Journal
Hedge Funds Suffer Big Losses on Biotech Rout
-
The Wall Street Journal
How a Vaccine Side-Effect Database Sowed Doubt in Vaccinations
-
The Washington Post
Gilead recalls vials of its Remdesivir covid drug in U.S. over glass contamination
-
Axios
Drug pricing coalition documents reveal data-blocking against employers
Dec 03, 2021
-
The Wall Street Journal
FDA Aims for Quick Review of Omicron Vaccines and Drugs
-
STAT
Califf asks Woodcock to stay in FDA leadership role if he’s confirmed
-
Financial Times
Fujifilm to double size of Teesside plant that makes Covid vaccine
-
Evaluate Vantage
Bridgebio sets its heart on besting Pfizer
Dec 02, 2021
-
STAT
Biden's new Covid plan: more boosters, free home testing, and 'monoclonal antibody strike teams'
-
Reuters
Australia's CSL in exclusive talks to buy Swiss Vifor Pharma - report
-
The Atlantic
What the J&J Vaccine Can Still Teach Us
-
JAMA
After 12 Years, NIH Director Francis S. Collins Seeks His Next Chapter
Dec 01, 2021
-
The New York Times
South African Company Nears License to Sell J. & J. Covid Shot Across Africa
-
Bloomberg
Biogen Loses Bid to Revive Patent on Tecfidera MS Drug
-
FierceBiotech
Sanofi snaps up Origimm for early-phase acne vaccine, opening new front in mRNA strategy
-
Reuters
U.S. FDA declines to approve BeyondSpring's neutropenia drug, shares plunge
Previous
